![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » KAMADA APPLIES FOR LICENSE FOR API CLINICAL TRIALS
KAMADA APPLIES FOR LICENSE FOR API CLINICAL TRIALS
September 13, 2005
Israel-based biopharmaceutical company Kamada has applied for a FDA license for the production of its Alpha 1-Proteinase Inhibitor (API) for Phase III clinical trials.
API is used for chronic replacement therapy for individuals with congenital deficiency of Alpha 1-Proteinase Inhibitor with demonstrable panacinar emphysema. Preliminary distribution of Kamada's API is now underway in several countries.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct